Welcome to our dedicated page for INVESTMENT MANAGERS SER TR II SEC filings (Ticker: SNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TAO Synergies Inc. filings document the public-company transition from Synaptogenix, its Nasdaq common stock listing, and disclosures tied to a TAO-focused digital asset treasury strategy. Recent Form 8-K reports cover the initial TAO purchase, BitGo custody, staking and trading services, Regulation FD disclosures, governance changes, and corrections to officer and director reporting.
Proxy materials disclose shareholder voting matters related to common stock issuances underlying convertible preferred stock and warrants, Nasdaq listing-rule approvals, consulting and placement-agent arrangements, capital structure, and governance. The filing record also identifies the company as an emerging growth company.
TAO Synergies (formerly Synaptogenix) has announced a special virtual stockholder meeting on August 6, 2025 to vote on three key proposals:
- Authorization to issue common stock underlying convertible preferred stock and warrants from a June 9, 2025 Securities Purchase Agreement, including 5,500 shares of Series D preferred stock convertible into 1,833,333 common shares at $3.00 per share, plus corresponding warrants
- Approval of amendments to the 2020 Equity Incentive Plan to increase available shares by 2 million and rename it to "TAO Synergies Inc. 2020 Equity Incentive Plan"
- Approval of a consulting agreement with James Altucher and Z-List Media, granting warrants for 1.2 million common shares at exercise prices ranging from $4.00 to $12.00 per share for crypto portfolio management and strategic services
The proposals require stockholder approval to comply with Nasdaq Listing Rules 5635(c) and 5635(d). The board recommends approval of all proposals. Record date for voting eligibility is June 9, 2025.
Synaptogenix (Nasdaq: SNPX) filed an 8-K reporting two material items: a leadership change and a corporate rebranding.
- CEO resignation: Dr. Alan J. Tuchman stepped down as Chief Executive Officer effective June 8 2025, but remains on the board and becomes Chief Medical Officer; his base salary is reduced to $7,500 per month.
- Name & ticker change: On June 26 2025 the company changed its name to TAO Synergies Inc. via a Delaware certificate of amendment. The Nasdaq symbol will switch from SNPX to TAOX on July 1 2025. No shareholder vote was required under DGCL §242.
The filing also corrects a prior 8-K that mistakenly said Dr. Tuchman resigned from the board; he continues as a director. Exhibits 3.1 and 99.1 provide the amendment and related press release.